Through RETHINKING Alzheimer’s disease (AD), the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are joining forces with the ambition of improving Alzheimer’s disease care pathway and the lives of people living with it. Officially launched on 29 April 2022, the project kicked off its operational activities with [...]
Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur, and the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterized by a decline in memory, thinking, [...]
Alzheimer’s disease (AD) – the most common cause of dementia – is one of the most significant medical and societal challenges of our time. It does not discriminate and affects everyone, across all generations – from the people who develop the condition, to the families that care for them and the taxpayers who fund health [...]
EBC is in Berlin this week for the 27th Alzheimer Europe Conference, focusing this year on the theme "care today, cure tomorrow". In partnership with MSD we are present at the exhibition and will hold a special symposium on the 4th October during lunch (beginning 12:45): Early intervention in Alzheimer’s disease: For a new understanding of [...]